Navigation Links
Advanced Life Sciences Enters Into Definitive Securities Purchase Agreements for $20 Million with New and Existing Institutional Investors
Date:12/11/2007

cial Group LLLP and CRT Capital Group LLC acting as co- placement agents in the transaction.

This news release is not an offer to sell or the solicitation of an offer to buy any securities of the Company.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation. The Company's lead candidate, cethromycin, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections including CAP. For more information, please visit us on the web at http://www.advancedlifesciences.com.

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements.

These risks and uncertainties include, among others, those relating to technology and product development, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences' filings with the Securities and Exchange Commission. Advanced Life Sciences undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.


'/>"/>
SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
3. Advanced Cell Technology Announces Proposed Financing
4. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference
7. CeloNova BioSciences Announces Worlds First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres
8. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
9. Advanced Bionics Deploys CEVA-TeakLite(TM) DSP Core to Enhance Its Harmony(TM) HiResolution(R) Bionic Ear System
10. NIH Announces Advanced Cell Technologys Single Cell Embryo Biopsy Technique as a Means to Derive Embryonic Stem Cells to be Considered for Federal Funding
11. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... 03, 2015 , ... Sterlitech Corporation introduces the compact, quiet, ... analytical laboratory equipment. With optimized features, such as PTFE-coated contact surfaces, an oil-free ... maintenance-free solution for a broad range of vacuum filtration applications. , Featuring a ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... the detection and quantification of partially hydrolyzed gluten in foods, has been accepted ... adopted the method “Partially Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 Competitive ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... Francois Vieillard as Sales & Marketing Director. , With more than 25 ... be responsible for reinforcing Tronics’ business development activities worldwide. He brings to the ...
(Date:7/30/2015)... CITY, Kan. , July 30, 2015 /PRNewswire/ ... ), a pet therapeutics company focused on the ... for companion animals, today announced that its strategic ... from a dose confirmation study of AT-016, an ... Aratana for the treatment of osteoarthritis pain in ...
Breaking Biology Technology:Sterlitech Launches New Line of Vacuum Pumps 2RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Tronics appoints Francois Vieillard as Sales and Marketing Director 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5
... Life Technologies Corporation today announced that its Ion Personal ... Innovative New Product "MIP" Awards luncheon hosted by CONNECT in ... disruptive technology in the gene sequencing field. Since ... uptake in research labs around the world and has been ...
...  Puma Biotechnology, Inc., a development stage biopharmaceutical company, ... trials of Puma,s investigational drug PB272 (neratinib) were ... Cancer Symposium that is currently taking place in ... below: Safety and Efficacy ...
... MIAMI BEACH, Fla., Dec. 9, 2011  As hundreds ... at the International Society for Fertility Preservation,s 2nd ... in reproductive endocrinology, urology and oncology announced the ... coalition to help newly diagnosed cancer patients in ...
Cached Biology Technology:Life Technologies' Ion Personal Genome Machine Receives San Diego's CONNECT Most Innovative New Product Award 2Life Technologies' Ion Personal Genome Machine Receives San Diego's CONNECT Most Innovative New Product Award 3Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium 2Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium 3Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium 4Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium 5Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium 6Experts Launch the Alliance for Fertility Preservation at the International Society for Fertility Preservation's 2nd World Congress 2Experts Launch the Alliance for Fertility Preservation at the International Society for Fertility Preservation's 2nd World Congress 3
(Date:7/27/2015)... , July 27, 2015   Zynx ... and experience-based clinical improvement solutions, today announced that ... is now available on Android smartphones and tablets. ... and post-care organizations can use ZynxCarebook to securely ... patient,s condition, streamline care transitions to other care ...
(Date:7/21/2015)... July 21, 2015 Passwords have proven ... in the recent U.S. Office of Personnel Management ... the infosec conundrum, but developers and end-users are ... address this dilemma, Biometrics-as-a-Service provider HYPR Corp. announced ... SDK for third party integration. ...
(Date:7/9/2015)... 07, 2015 Research ... of the "Biometrics for Banking; Market & ... report to their offering. The adoption ... this growth and the forecast is that by ... for companies involved in delivering biometric systems to ...
Breaking Biology News(10 mins):Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... burden of malaria remains the subject of "best guesses," ... remains "driven by perceptions and politics, rather than an ... in PLoS Medicine. , Simon Hay and Robert Snow ... that it has been almost 40 years since the ...
... in Fantastic Voyage, doctors might soon be able to ... find where and how much of a cancer treatment ... in a study published today in the open access ... and quantify molecules within individual mammalian or bacterial cells. ...
... a single gene, researchers can prevent skin stem cells from ... epidermal, sebaceous and hair cells. They say this finding could ... in the lab, for both research and potential therapies. , ... the ability to differentiate into multiple types of tissues, one ...
Cached Biology News:Fantastic Voyage: A new nanoscale view of the biological world 2Researchers identify a key regulator for skin stem cells 2
Request Info...
Immunogen: Heat inactivated bacterial cells of Salmonella enteriditis,paratyphi and typhimurium Storage: 4 C...
US Pharmacopoeia Purified-Water/Water-for-Injection Quality Water...
... Clone/PAD: 3B8A10. ... to the C-terminal region ... Specificity: Specific for the ... Reactivity: Human (positive control: ...
Biology Products: